キナゾリン・リガンドは,選択的なSTAT3阻害とG-四重複安定化により癌細胞死を誘発する

Jan Jamroskovic¹, Mara Doimo¹, Karam Chand²

¹Department of Medical Biochemistry and Biophysics , Umeå University , Umeå 90736 , Sweden.

Journal of the American Chemical Society

|January 29, 2020

まとめ

新しいキナゾリン化合物は,G四重複 (G4) DNA構造とSTAT3タンパク質の両方を標的にします. この二重作用は,がん細胞の増殖とDNA損傷反応を抑制し,がんに対する新しい治療戦略を提供します.

科学分野:

薬剤化学
分子生物学
癌研究

背景:

シグナルトランスデューサーとトランスクリプション3 (STAT3) のアクティベーターは,増殖やDNA損傷反応のような主要な癌の特徴を調節します.
G四重複 (G4) DNA構造は,癌細胞における複製ストレスとDNA損傷における役割のために,がん治療の有望な標的である.

研究の目的:

G4DNA構造とSTAT3タンパク質の両方を標的とした新しいキナゾリン基化合物の設計と合成.
癌細胞の増殖を抑制し,DNAの損傷を誘導するこれらの化合物の有効性を評価する.

主な方法:

化合物の結合とG4の安定化を特徴付けるために,in vitro検査,核磁気共振 (NMR),および分子動力学シミュレーションを使用した.
STAT3抑制,G4構造形成,DNA複製,アポトーシスを評価するためにヒト培養細胞を治療した.
癌細胞と非癌細胞の比較感度分析が行われました.

主要な成果:

合成された化合物はSTAT3に結合し,G4DNA構造を安定させる.
化合物は,STAT1に影響を与えることなく,STAT3のリン酸化依存活性化を阻害し,細胞内のG4構造の形成を増加させます.
治療を受けた癌細胞は,正常細胞と比較して,より遅いDNA複製,活性化DNA損傷チェックポイント,および増加したアポトーシスを示します.

結論:

この研究では,G4 DNAとSTAT3に対する二重活性を持つ新種のキナゾリン化合物が報告されています.
これらの化合物は,がん細胞増殖とDNA損傷反応経路の両方を標的として,がん治療における有望な新しいアプローチを表しています.

さらに関連する動画

10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.6K

08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.4K

関連する概念動画

02:34

Inhibition of Cdk Activity

5.5K

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

5.5K

01:31

The Intrinsic Apoptotic Pathway

8.1K

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

8.1K

01:15

Drugs that Stabilize Microtubules

2.5K

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

2.5K

01:10

Drugs that Destabilize Microtubules

3.5K

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

3.5K

02:57

Targeted Cancer Therapies

8.6K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

8.6K

01:20

The JAK-STAT Signaling Pathway

11.6K

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...